Please use this identifier to cite or link to this item: http://hdl.handle.net/11189/8698
DC FieldValueLanguage
dc.contributor.authorEbokaiwe, Azubuike Peteren_US
dc.contributor.authorNjoya, Emmanuel Mfotieen_US
dc.contributor.authorSheng, Yuwenen_US
dc.contributor.authorZhang, Zhonghuien_US
dc.contributor.authorLi, Shengen_US
dc.contributor.authorZhou, Zongyuanen_US
dc.contributor.authorQiang, Zheen_US
dc.contributor.authorPeng, Tingen_US
dc.contributor.authorHussein, Ahmed A.en_US
dc.contributor.authorZhang, Guolinen_US
dc.contributor.authorLu, Xiaoxiaen_US
dc.contributor.authorLi, Linen_US
dc.contributor.authorWang, Feien_US
dc.date.accessioned2022-07-22T10:17:03Z-
dc.date.available2022-07-22T10:17:03Z-
dc.date.issued2020-
dc.identifier.citationEbokaiwe, A.P., Njoya, E.M., Sheng, Y. et al. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells. Toxicology and Applied Pharmacology, 404: 1-12. [https://doi.org/10.1016/j.taap.2020.115203]en_US
dc.identifier.issn0041-008X-
dc.identifier.urihttp://hdl.handle.net/11189/8698-
dc.description.abstractIndoleamine 2,3 dioxygenase (IDO) is upregulated in many tumor types, including breast cancer, and plays a reputable role in promoting tumor immune tolerance. The importance of the immunosuppressive mechanism of IDO by suppressing T-cell function has garnered profound interest in the development of clinical IDO inhibitors. Herein, we established a screening method with cervical HeLa cells to induce IDO expression using interferon-γ (IFN-γ). After screening our chemical library, we found that salinomycin potently inhibited IFN-γ-stimulated kynurenine synthesis with IC50 values of 3.36–4.66 μM in both human cervical and breast cancer cells. Salinomycin lowered the IDO1 and IDO2 expression with no impact on the expression of tryptophan-2,3-dioxygenase. Interestingly, salinomycin potently repressed the IDO1 enzymatic activity by directly targeting the proteins in cells. Molecular docking revealed an alignment that favors nucleophilic attack of salinomycin in the catalytic domain of IDO1. Activation of the Janus kinase/signal transducer and activator of transcription (JAK/ STAT) pathway by IFN-γ was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/ 3 phosphorylation. Moreover, it inhibited IFN-γ-induced activation of the nuclear factor (NF)-κB pathway by inhibiting IκB degradation and NF-κB phosphorylation without affecting BIN1 expression. Furthermore, salinomycin significantly restored the proliferation of T cells co-cultured with IFN-γ-treated breast cancer cells and potentiated antitumor activity of cisplatin in vivo. These findings suggest that salinomycin suppresses kynurenine synthesis by inhibiting the catalytic activity of IDO1 and its expression by inhibiting the JAK/STAT and NF-κB pathways. Salinomycin warrants further investigation as a novel dual-functional IDO inhibitor for cancer immunotherapy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofToxicology and Applied Pharmacologyen_US
dc.subjectIndoleamine-2,3-Dioxygenaseen_US
dc.subjectKynurenineen_US
dc.subjectSalinomycinen_US
dc.subjectInterferon γen_US
dc.subjectBreast canceren_US
dc.titleSalinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cellsen_US
dc.identifier.doihttps://doi.org/10.1016/j.taap.2020.115203-
dc.typeArticleen_US
Appears in Collections:Appsc - Journal Articles (DHET subsidised)
Files in This Item:
File Description SizeFormat 
Salinomycin_promotes_T-cell_proliferation.pdf3.17 MBAdobe PDFView/Open
Show simple item record

Page view(s)

103
Last Week
0
Last month
6
checked on Sep 2, 2026

Download(s)

54
checked on Sep 2, 2026

Google ScholarTM

Check

Altmetric


Items in Digital Knowledge are protected by copyright, with all rights reserved, unless otherwise indicated.